DYAI
Dyadic International, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.52
+3.89%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 3.5M | 1.2M | 3.5M | 2.9M | 2.9M |
| Cost of Revenue | 2.4M | 2.3M | 1.2M | 2.0M | 2.1M |
| Gross Profit | 1.1M | (1.1M) | 2.3M | 923.0K | 807.1K |
| Operating Expenses | |||||
| R&D Expense | 1.6M | 2.2M | 2.0M | 3.3M | 4.5M |
| SG&A Expense | 6.2M | 5.8M | 6.1M | 5.8M | 6.4M |
| General & Admin Expense | 6.2M | 5.8M | 6.1M | 5.8M | 6.4M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 682.7K | (1.9M) | 22.6K | 38.4K | 49.9K |
| Total Operating Expenses | 8.5M | 6.1M | 8.2M | 9.2M | 11.0M |
| Cost and Expenses | 10.9M | 8.4M | 9.4M | 11.1M | 13.1M |
| Operating Income (EBIT) | (7.4M) | (7.1M) | (5.9M) | (8.2M) | (10.2M) |
| Non-Operating | |||||
| Interest Income | 243.4K | 284.1K | 457.0K | 416.7K | 180.4K |
| Interest Expense | 418.9K | 455.9K | 428.0K | — | — |
| Net Interest Income | (175.5K) | (171.8K) | 29.0K | 416.7K | 180.4K |
| Other Non-Op Income/Expense | (205.1K) | (218.7K) | 91.7K | 1.4M | 430.4K |
| Non-Operating Income (excl Interest) | (213.8K) | (237.2K) | (519.6K) | (38.4K) | (49.9K) |
| EBT (Pre-Tax Income) | (7.6M) | (7.4M) | (5.8M) | (6.8M) | (9.7M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (7.6M) | (7.4M) | (5.8M) | (6.8M) | (9.7M) |
| Earnings from Cont. Ops | (7.6M) | (7.4M) | (5.8M) | (6.8M) | (9.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (7.6M) | (7.4M) | (5.8M) | (6.8M) | (9.7M) |
| Per Share | |||||
| Basic EPS | ($0.21) | ($0.23) | ($0.20) | ($0.24) | ($0.34) |
| Diluted EPS | ($0.21) | ($0.23) | ($0.20) | ($0.24) | ($0.34) |
| Revenue Per Share | $0.10 | $0.04 | $0.12 | $0.10 | $0.10 |
| Shares | |||||
| Basic Shares Outstanding | 36.4M | 32.6M | 29.3M | 28.8M | 28.4M |
| Diluted Shares Outstanding | 36.4M | 32.6M | 29.3M | 28.8M | 28.4M |
| Profitability Metrics | |||||
| EBITDA | (7.2M) | (6.9M) | (5.4M) | (8.2M) | (10.1M) |
| D&A | 18.3K | — | — | 38.4K | — |
| EBIT | (7.2M) | (6.9M) | (5.4M) | (8.2M) | (10.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026